Form 4: Spyre Therapeutics Director Acquires Stock Options

Director Jeffrey W. Albers acquired stock options for 11,323 shares of Spyre Therapeutics, Inc. common stock on May 14, 2024.

Summary

• On May 14, 2024, Jeffrey W. Albers, a director of Spyre Therapeutics, Inc., acquired stock options to purchase 11,323 shares of the company's common stock.
• The exercise price of these options is $39.29 per share.
• The options vest in 12 equal monthly installments starting May 14, 2024, contingent upon Albers' continued service with the company.
• The options expire on May 14, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative news, but rather provides transparency into insider transactions.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for directors and officers of publicly traded companies when they have transactions involving the company's securities. It provides transparency into insider activity.

Stakeholder Impact

• Shareholders may view this as a positive sign if they believe the director's interests are aligned with theirs through stock ownership.

Key Dates